ALC-2201

ALC-2201 is a generic drug candidate developed by **Korea Arlico Pharm** for the treatment of **cardiovascular system** disorders. As a generic formulation, ALC-2201 is designed to be bioequivalent to an existing reference listed drug, providing a cost-effective alternative for chronic cardiovascular conditions. The project is part of Korea Arlico Pharm's strategic expansion into the chronic disease market, specifically targeting high-value cardiovascular therapies. While the specific active pharmaceutical ingredient (API) is not explicitly detailed in the company's high-level pipeline disclosures, the candidate is categorized as a small molecule generic within their R&D portfolio.